BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 9771960)

  • 21. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
    Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
    Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
    Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
    Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence supporting a role for mitochondrial respiration in apoptosis induction by the synthetic retinoid CD437.
    Hail N; Youssef EM; Lotan R
    Cancer Res; 2001 Sep; 61(18):6698-702. PubMed ID: 11559538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity of the retinoid-related molecules (E)-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor gamma and retinoid-independent pathways.
    Parrella E; Giannì M; Fratelli M; Barzago MM; Raska I; Diomede L; Kurosaki M; Pisano C; Carminati P; Merlini L; Dallavalle S; Tavecchio M; Rochette-Egly C; Terao M; Garattini E
    Mol Pharmacol; 2006 Sep; 70(3):909-24. PubMed ID: 16788091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model.
    Langdon SP; Crew AJ; Ritchie AA; Muir M; Wakeling A; Smyth JF; Miller WR
    Eur J Cancer; 1994; 30A(5):682-6. PubMed ID: 8080688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR.
    Holmes WF; Soprano DR; Soprano KJ
    J Cell Biochem; 2003 May; 89(2):262-78. PubMed ID: 12704790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correspondence re: A. Kumar et al., cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res., 61: 7552-7555, 2001.
    Garattini E; Gianni' M; Terao M
    Cancer Res; 2002 Apr; 62(7):2192-3; author reply 2193-4. PubMed ID: 11929843
    [No Abstract]   [Full Text] [Related]  

  • 30. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
    Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines.
    Holmes WF; Soprano DR; Soprano KJ
    J Cell Physiol; 2004 Jun; 199(3):317-29. PubMed ID: 15095280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells.
    Sun SY; Yue P; Mao L; Dawson MI; Shroot B; Lamph WW; Heyman RA; Chandraratna RA; Shudo K; Hong WK; Lotan R
    Clin Cancer Res; 2000 Apr; 6(4):1563-73. PubMed ID: 10778990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas.
    Rose WC; Basler GA
    In Vivo; 1990; 4(6):391-6. PubMed ID: 2103379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells.
    Dawson MI; Chao WR; Pine P; Jong L; Hobbs PD; Rudd CK; Quick TC; Niles RM; Zhang XK; Lombardo A
    Cancer Res; 1995 Oct; 55(19):4446-51. PubMed ID: 7671258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus.
    Marchetti P; Zamzami N; Joseph B; Schraen-Maschke S; Méreau-Richard C; Costantini P; Métivier D; Susin SA; Kroemer G; Formstecher P
    Cancer Res; 1999 Dec; 59(24):6257-66. PubMed ID: 10626821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells.
    Sun SY; Yue P; Chen X; Hong WK; Lotan R
    Cancer Res; 2002 Apr; 62(8):2430-6. PubMed ID: 11956107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic retinoid CD437 induces cell-dependent cycle arrest by differential regulation of cell cycle associated proteins.
    Shyu RY; Lin DY; Reichert U; Jiang SY
    Anticancer Res; 2002; 22(5):2757-64. PubMed ID: 12529993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of 13,14-dihydro-15-deoxy-delta7-prostaglandin-A1-methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo.
    Sasaki H; Niimi S; Akiyama M; Tanaka T; Hazato A; Kurozumi S; Fukushima S; Fukushima M
    Cancer Res; 1999 Aug; 59(16):3919-22. PubMed ID: 10463583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.